AI in Clinical Trials Market

Market Outlook

The global AI in clinical trials market, valued at USD 3.48 billion in 2025, is projected to reach USD 3.96 billion in 2026 and USD 11.61 billion by 2035, representing a CAGR of 12.7% during the forecast period 2026 to 2035.

Market Report: Key Takeaways

Market Size & Trends

• In terms of trial phase, phase II holds the largest share (nearly 55%) of the current market.
• With respect to type of offering, services segment dominates the current market.
• Based on the deployment mode, cloud-based AI solutions capture the largest share (around 75%) of the current market, and the trend is unlikely to change in the future.
• In terms of therapeutic area, oncological disorders are expected to hold the largest market share (more than 40%) by 2035.
• With respect to technology exposure, machine learning dominates the current market.
• Based on end-user, biotechnology and pharmaceutical companies capture the largest share of the current market, and the trend is unlikely to change in the future.
• In terms of geographical region, the Asia-Pacific region dominates the current market by securing over 40% share within the AI in clinical trials industry.

Market Introduction

The global AI in clinical trials market is expanding rapidly, driven by the growing demand for improved patient recruitment and retention, real-time data collection, and enhanced cost and data efficiencies. Rising investment activity and cross-industry partnerships are further broadening opportunities in this domain.

Clinical trials account for nearly half of the time and capital expenditure in the drug development process. However, over the past few decades, the success rate of a drug candidate advancing from conventional clinical trials to marketing approval has remained relatively constant at approximately 10%, placing considerable financial burden on sponsors and causing significant delays in bringing therapies to market. Key challenges contributing to this low success rate of conventional trials include inadequate study design, incomplete patient recruitment, improper subject stratification, and high participant attrition.

To address these challenges, stakeholders have increasingly turned to AI to streamline clinical trial processes. Artificial intelligence enables integration and analysis of large data volumes, helping sponsors optimize trial design, improve site selection, enhance patient stratification, and refine treatment evaluation, ultimately strengthening the entire drug development continuum. As regulatory agencies, such as the FDA and EMA continue to develop frameworks accommodating AI-driven trial methodologies, institutional confidence in these tools is growing, positioning AI as a foundational element of next-generation clinical research rather than a supplementary capability.

Market Segmentation

Based on the research, we have segmented the AI in Clinical Trials Market into trial phase, type of offering, deployment mode, therapeutic area, technology exposure, end-user and geographical regions.

Distribution by Trial Phase

• Phase I
• Phase II
• Phase III

Distribution by Type of Offering

• Software
• Services

Distribution by Deployment Mode

• Cloud-based
• On-premises

Distribution by Therapeutic Area

• Oncological Disorders
• Infectious Diseases
• CNS disorders
• Metabolic Disorders
• Immunological Disorders
• Cardiovascular Disorders
• Other Disorders

Distribution by Technology Exposure

• Machine Learning
• Molecular Modeling and Simulation
• Deep Learning
• Omics Integration
• Generative Model
• Other Technologies

Distribution by End-user

• Biotechnology and Pharmaceutical Companies
• Academic Research Institutes
• Other End-users

Distribution by Geographical Regions

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Australia
  • India
• Middle East and North Africa
  • Saudi Arabia
  • UAE
  • Egypt
• Latin America
  • Brazil
  • Mexico
  • Argentina

AI in Clinical Trials Market Key Insights

What are the Key Drivers for AI in Clinical Trials Market Growth?

• Improved Patient Retention Rate: AI helps address key challenges patients face, such as frequent site visits, time constraints, and associated costs. By leveraging AI, sponsors can reduce the need for physical travel by enabling remote participation across multiple trial stages, ultimately lowering the overall time and financial commitment for patients. Moreover, telehealth platforms integrated within AI-enabled trial frameworks allow healthcare professionals to conduct regular follow-ups and monitor patient activity with greater consistency.
• Real-time Data Collection: The widespread adoption of mobile applications, wearable medical devices, and telemedicine, now enable continuous, real-time collection of patient data throughout the course of a clinical trial. This capability allows healthcare professionals to monitor patient health more accurately, identify emerging trends, and make timely adjustments to study protocols, thereby improving overall research quality. Beyond data collection, these technologies have also streamlined ancillary trial processes, including patient recruitment, retention, and data management, contributing to enhanced trial efficiency with electronic health records. The growing recognition of these benefits is accelerating the adoption of AI in clinical trials.

What are the Regulatory Guidelines for the Usage of AI in Clinical Trials from Different Regulatory Bodies?

• The USFDA Guidance: The FDA’s draft guidance related to the usage of AI to support regulatory decision-making outlines a seven-step risk-based credibility assessment for AI models. Higher-risk AI applications, particularly those that can affect patient safety or trial efficacy will require rigorous validation, documentation of model training, and lifecycle monitoring with tools like Algorithm Change Protocols. Moreover, sponsors must demonstrate AI reliability for specific contexts of use-cases, including trial design, recruitment, and data analysis.
• EMA and EU Frameworks: The EMA and EU frameworks support the utilization of AI in clinical trials through its Big Data Strategy. The strategy focuses on automation, insights, and decision support while managing risks. Notably, the EU AI Act classifies AI used in clinical trials as risky, requiring stringent requirements like transparency in decision logic and compliance for medical devices. Additionally, sponsors must ensure ethical data handling and obtain regulatory approvals before deploying AI.

Industry Experts on AI in Clinical Trial Market

The market for AI in clinical trials has a transformative future and is likely to remain progressive in the future. Highlighting this trend, Jennifer Duff (Executive Vice President and General Manager of Zelta), stated that, “AI is going to optimize efficiency, bring down costs and manual effort, and improve traceability and quality. It will also bring together really good science between the human experts and the added controls on the AI side. There’s a significant amount of investment in this domain right now. Once we stand up the ability to support ingestion and implementation of this, and integrate with downstream workflows, that adoption will add immediate value.”

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the interviews conducted with the following individuals:

• Co-founder, Chief Executive Officer and Chief Technology Officer, Small Company, Switzerland
• Founder and Chief Executive Officer, Mid-Sized Company, US
• Founder and Chief Executive Officer, Small Company, US
• Co-founder and Executive Director, Mid-Sized Company, US
• Chief Technology Officer, Chief Commercial Officer, Chief Delivery Officer, Mid-Sized Company, Head of Marketing, Mid-Sized Company, US

In addition, the market report includes transcripts of the following third-party discussions:

• Chief Science Officer, Large Company, US; Co-Founder and Chief Executive Officer, Mid-Sized Company, US; Chief Executive Officer, Mid-Sized Company, US; Associate Professor and Blue Cross California Distinguished Professor, Large Organization, US
• EVP, Chief Information, Technology, and Product Officer, Large Company, US
• Co-Founder and Chief Executive Officer, Mid-Sized Company, US
• Chief Technology Officer, Mid-Sized Company, US
• Director of the Office of Medical Policy (CDER), Large Organization, US
• Professor of Medicine, Large Organization, US; Program Manager, Large Organization, US; Director, Bioethics Lead, Large Company, US; Associate Dean, Human Research Protections and Director of the Human Research Protections Program, Large Organization, US; Executive IRB Chair and VP of IBC Affairs, Large Company, US
• Hematologist, AI Specialist, and Research Group Leader, Large Organization, Germany
• Cardiologist and Associate Director of the Accelerator for Clinical Transformation Research Group, Large Organization, US
• Heart Failure Cardiologist and Researcher, Large Organization, US
• Senior Community Development Manager, Mid-Sized Company, Netherlands

Market Share Insights

Which Trial Phase Holds the Largest Share in AI in Clinical Market?

• In 2026, the phase II clinical trials hold the highest market share (around 55%). This growth can be attributed to various advantages offered by AI solutions in phase II clinical trials (considered a critical decision point) where companies assess proof-of-concept, optimal dosing, and efficacy in larger patient groups, with traditional success rates of only 30-40%.
• The market for phase III clinical trials is likely to grow at a higher CAGR during the forecast period due to the generation of large amounts of data (up to 3.6 million data points per study), which necessitates the use of advanced AI for real-time analysis, risk monitoring and adaptive designs to manage complexity and reduce costs.

Will Oncological Disorders Hold the Largest Share within the AI in Clinical Trials Industry Through 2035?

• By 2035, the oncological disorders segment is likely to hold the largest share (nearly 50%) within the AI in clinical trials market. Further, this segment is expected to witness a significant growth rate during the forecast period.
• This trend is largely driven by the extensive data volume and inherent complexity of oncology clinical trials, creating a strong use case for AI-driven analytics, patient stratification, and decision support.

What is the Market Opportunity for Technology Exposure?

• Based on the AI in clinical trials market forecast, machine learning technology holds the largest share within the current global market. This dominance is due to its superior versatility in handling complex clinical datasets, enabling predictive modeling, and real-time insights.
• In addition to this, we anticipate the generative model segment to witness a higher CAGR through 2035. Generative models create realistic synthetic patient data, which drives faster adoption and higher growth compared to other technology segments.

Which Deployment Mode Dominates the AI in Clinical Trials Market?

• Cloud-based deployment of AI in clinical trials currently dominates the market, accounting for the largest share (around 75%) due to its scalability, cost efficiency, and ability to support collaboration across distributed trial stakeholders. This segment is also expected to grow at an accelerated pace through 2035, driven by the growing adoption of decentralized trial models and the rising need to manage large, complex, and data-intensive AI applications.

Scope of AI in Clinical Trials Market Report

Frequently Asked Questions